Jan Rutherford

Jan leads our investor relations activities and works closely with the limited partners across our funds.

With an operational and commercial background in the pharmaceutical industry, Jan also leads SEP’s healthcare investment activities, with a particular interest in digital health. She jointly led SEP’s investment in Dotmatics, a global scientific informatics software provider.

Jan was heavily involved in SEP’s investment in BioVex, a cancer therapeutics company, and supported management through its sale to Amgen in a $1bn deal. She also led SEP’s investment in Exco InTouch, a leading provider of mobile patient communication and management solutions for clinical research and healthcare providers, which was sold to Nordic Capital-backed ERT.

Outside of SEP, Jan is a Trustee of the National Deaf Children’s Society.